Synteract Bolsters Its Oncology, Neuro Degenerative and Rare Disease Centers of Development with Two New Executives

    0
    224
    Reading Time: 2 minutes

    Christopher Heckman to focus on Oncology Center of Development as Dr.
    Art Wamil joins as lead neurologist

    RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–lt;a href=”https://twitter.com/hashtag/CRO?src=hash” target=”_blank”gt;#CROlt;/agt;–Synteract,
    an innovative CRO partnering with biotech and pharma companies to bring
    new medicines to market, continues its commitment to specialized Centers
    of Development as it adds two new executives to the team. Christopher
    Heckman, RN, BSN, joins as the vice president for oncology development
    and will build the company’s Center of Development in Oncology
    while Art Wamil, M.D., Ph.D., joins as senior medical director and lead
    neurologist to further strengthen its Neuro
    Degenerative
    and Rare
    Disease
    Centers of Development. Since focusing its expertise in five Centers
    of Development
    in 2018, Synteract has seen increasing opportunities
    in its biopharma business, especially in oncology and neuro degenerative
    areas, coming from both rare disease and non-rare indications.

    With 23 years of clinical research experience, Christopher Heckman is an
    accomplished leader with management, clinical and business development
    experience. He possesses a broad experience base across the drug
    development lifecycle, with both strategic and operational lines of
    responsibility, with hands-on engagement in all development phases as
    well as global registration experience. Previously, he has held
    leadership positions for portfolio management with both large and small
    CROs and managed an oncology product to regulatory approval for a major
    pharmaceutical company.

    Dr. Wamil is a neurologist/electrophysiologist with more than 20 years
    of scientific and medical experience in the healthcare and
    biotech/pharmaceutical industries, primarily in neurology,
    neuroscience/CNS, and diagnostic medicine fields, working with both
    adults and children. He has co-authored more than 30 scientific papers
    and over 70 scientific abstracts, posters and presentations, and is an
    active member of AAN,
    AES,
    MDS,
    AHA/ASA,
    and AMA.

    CEO
    Steve Powell
    says, “We are delighted to add these experienced
    leaders to the organization as they both offer breadth and depth of
    knowledge in their respective therapeutic areas and a keen understanding
    of what is needed to move studies through the complex clinical
    development process. Their years of experience and expansive scientific
    and medical capabilities will add to our already strong teams. I am
    confident they will be valuable additions in informing the best
    strategies for the trials we undertake on our clients’ behalf.”

    Dr. Wamil received his M.D. and Ph.D. from Medical
    University of Lublin
    (MUL) in Poland and completed his internships,
    residencies and fellowships at MUL, Vanderbilt
    University
    , and Northwestern
    University/Children’s Memorial Hospital
    . He trained in
    electrophysiology/epilepsy and previously served on the faculty in
    Neurology and Anesthesiology at Vanderbilt University Medical Center for
    over 10 years.

    Mr. Heckman received his Bachelor of Science in Nursing and Organic
    Chemistry from Misericordia
    University
    and completed coursework for an MBA in Finance at the Iacocca
    Institute at Lehigh University
    , both in Pennsylvania.

    About Synteract

    Bringing
    Clinical Trials to Life
    ” represents Synteract’s commitment to engage
    with drug developers, patients, investigators, and regulatory experts,
    to bring insights to action and make better therapies a reality. With
    800 employees across 21 countries, Synteract
    supports biotech and pharma companies across all phases of drug
    development to help bring new medicines to market. Synteract has
    conducted nearly 4,000 studies on six continents and in more than 60
    countries. It has contributed to more than 240 product approvals.
    Synteract offers a notable depth of therapeutic expertise in oncology,
    dermatology, neuro degenerative, pediatrics, and rare and orphan
    diseases. Connect on LinkedIn
    and Twitter.

    Contacts

    Beth Walsh
    [email protected]
    760-230-2424